We describe a long-term observational study of a large cohort of patients with sporadic inclusion body myositis and propose a sporadic inclusion body myositis weakness composite index that is easy to perform during a clinic. Data collection from two groups of patients (Paris and Oxford) was completed either during a clinic visit (52%), or by extraction from previous medical records (48%). One hundred and thirty-six patients [57% males, 61 (interquartile range 55-69) years at onset] were included. At the last visit all patients had muscle weakness (proximal British Medical Research Council scale 53/5 in 48%, distal British Medical Research Council scale 53/5 in 40%, swallowing problems in 46%). During their follow-up, 75% of patients had significant walking difficulties and 37% used a wheelchair (after a median duration from onset of 14 years). The sporadic inclusion body myositis weakness composite index, which correlated with grip strength (correlation coefficient: 0.47; P 5 0.001) and Rivermead Mobility Index (correlation coefficient: 0.85; P 5 0.001), decreased significantly with disease duration (correlation coefficient: À 0.47; P 5 0.001). The risk of death was only influenced by older age at onset of first symptoms. Seventy-one (52%) patients received immunosuppressive treatments [prednisone in 91.5%, associated (in 64.8%) with other immunomodulatory drugs (intravenous immunoglobulins, methotrexate or azathioprine) for a median duration of 40.8 months]. At the last assessment, patients who had been treated were more severely affected on disability scales (Walton P = 0.007, Rivermead Mobility Index P = 0.004) and on the sporadic inclusion body myositis weakness composite index (P = 0.04). The first stage of disease progression towards handicap for walking was more rapid among patients receiving immunosuppressive treatments (hazard ratio = 2.0, P = 0.002). This study confirms that sporadic inclusion body myositis is slowly progressive but not lethal and that immunosuppressive treatments do not ameliorate its natural course, thus confirming findings from smaller studies. Furthermore, our findings suggest that immunosuppressant drug therapy could have modestly exacerbated progression of disability. The sporadic inclusion body myositis weakness composite index might be a valuable outcome measure for future clinical trials, but requires further assessment and validation.
Introduction
Sporadic inclusion body myositis (IBM) is characterized by slowly progressive, asymmetric, atrophy and weakness of both proximal and distal muscles, most prominently affecting the finger and wrist flexors and quadriceps (Griggs et al., 1995) . Given pathological evidence of muscle inflammation (Needham and Mastaglia, 2007) , and expansion of oligoclonal CD8 cells (Dimitri et al., 2006) , treatment aimed at reducing inflammation has been pursued. Although some case reports (Lotz et al., 1989; Sayers et al., 1992; Beyenburg et al., 1993; Lindberg et al., 1994; Badrising et al., 2005) have suggested that immunotherapies may slow down or arrest disease progression [e.g. after alemtuzumab (Campath Õ , anti-CD52; Dalakas et al., 2009) or anti-T lymphocyte globulin (Lindberg et al., 2003) ], eight prospective, double-blind studies have indicated that immunosuppressive or modulator regimens have minimal or no benefit in patients with sporadic IBM (Leff et al., 1993; Dalakas et al., 1997 Dalakas et al., , 2001 Walter et al., 2000; Muscle Study Group, 2001 , 2004 Badrising et al., 2002; Rutkove et al., 2002) . Over the past several years, the identification of amyloid deposits (Mendell et al., 1991) has raised the possibility that sporadic IBM may be a primary degenerative disorder of muscle (Askanas and Engel, 2008; Askanas et al., 2009) , but this remains much debated (Greenberg, 2009) . Partly because of the lack of evidence of benefit from immunosuppressive drugs, and knowing of the potentially serious sideeffects of such drug therapy, particularly in the older population, historically most patients with sporadic IBM followed in Oxford have not received immunosuppressive drugs. They have received supportive management, as for patients with other myopathies without specific drug treatment such as the muscular dystrophies. On the other hand, and influenced by case reports of clinical improvement under therapy, patients with sporadic IBM followed in Pitié -Salpê triè re Hospital (Paris) received immunosuppressive drugs and/or intravenous immunoglobulins (IVIg) much more frequently. The aim of this observational study was to describe the rate and nature of progression of disability of sporadic IBM in a large number of patients, to evaluate muscle strength by different methods to finally propose a sporadic IBM weakness composite index (IWCI) and to determine whether these alternative approaches to management influenced the course of the disease in terms of morbidity, disability or mortality.
Materials and methods

Patients
Diagnostic criteria for sporadic IBM were the Griggs' criteria (Griggs et al., 1995) , defining definite and possible IBM, and Hilton-Jones' criteria of clinically defined IBM and possible sporadic IBM, as reviewed in recent workshops (Benveniste and Hilton-Jones, 2010; Hilton-Jones et al., 2010) . All known patients with sporadic IBM seen either in Paris, France at the Pitié -Salpê triè re Hospital (Internal Medicine Department and Institute of Myology) or in Oxford, UK at the John Radcliffe Hospital (Neurology Department) between 1990 and 2008 were identified from clinical and pathological records. The study was approved by the Ethical Review Committee of both Hospitals. An anonymized clinical research form was completed for each patient with the information being derived from: (i) during the course of the study, interview of the patient during their last routine appointment; (ii) their medical records relating to previous routine appointments; or (iii) phone interview for eight patients who were being followed up elsewhere than Paris or Oxford. The clinical research form had items concerning patient details (age, sex, past history and treatments unrelated to sporadic IBM), the onset of the disease (date, first symptoms and signs), age at which the patient began using a cane, walker or wheelchair, and the physical examination at the last visit including manual muscle strength testing using the six-point British Medical Research Council (MRC) scale on deltoids, biceps brachii and triceps, wrist flexors, finger extensors and flexors, psoas, hip abductors and adductors, quadriceps, foot flexors and extensors, neck extensors and flexors. To evaluate strength and mobility, two functional scales were performed: Walton scale (Laforet et al., 2000) and Rivermead Mobility Index (Collen et al., 1991) for disability. Grip strength was also evaluated by using a hand grip dynamometer (T.K.K. 5401; Takei Scientific Instruments). The IWCI was based on the measurement of nine items (Table 1) , easily calculated during a visit with a maximal score of 100 (normal strength). The parameters chosen were based on our clinical experience of assessing patients with sporadic IBM. It evaluated muscles (force of finger flexion and quadriceps) and functions (limb girdle, axial weakness, swallowing difficulties) particularly affected by sporadic IBM. Given the difficulties with the MRC scale, particularly in terms of inter-and intra-observer reliability when assessing minor variations in strength (e.g. between 4 + , 4 and 4 À), we chose to use quantitative timed measurements (Table 1) for proximal and axial muscle function. For evaluating finger flexion weakness, characteristic of sporadic IBM, we used the following equivalents to describe finger flexion weakness, which we believe closely reflect clinical observation: MRC 5, normal grip strength; MRC 4, firm grip with all fingers but weaker than normal; MRC 3, can flex all fingers to place fingertips on palm, but not against resistance; MRC 2, one or more fingertips cannot be flexed on to palm; MRC 1, flicker of movement only; and MRC 0, no movement. Finally, details of treatments specifically for sporadic IBM (if any) were recorded. The clinical examinations were performed by four physicians highly experienced in dealing with sporadic IBM (O.B., M.I.L., B.E., D.H.-J.) who standardized their practice during two meetings.
Muscle biopsies
All patients had a diagnostic biopsy, with tissue frozen and stored at À 80 C. The day of the biopsy is referred to as the date of diagnosis.
Items from the pathology report, such as the presence of inflammation, partially invaded fibres, major histocompatibility complex (MHC) class I antigen upregulation, vacuoles (rimmed or not), ragged red fibres, cytochrome oxidase negative fibres, were recorded on the clinical research form. Some of the biopsy specimens were examined by electron microscopy or stained using TDP-43 (TAR DNA-binding protein 43, 10782-2-AP, ProteinTech Group, dilution 1 : 100), or p62 (p62/SQSTM1 (H-290) Santa Cruz Biotech, dilution 1 : 100). The pathological analyses were performed by two experienced muscle pathologists (O.D., W.S.) who assessed their intra-reader reliability in looking at muscle biopsy slides during two meetings. were found between patients from Paris or Oxford for all the characteristics reported in Table 2 (data not shown). Forty patients fulfilled the Griggs' criteria for definite sporadic IBM (Griggs et al., 1995) i.e. invasion of non-necrotic fibres by mononuclear cells, vacuolated muscle fibres and intracellular amyloid deposits (evidenced by electron microscopy or TDP-43 or p62 immunostainings). These patients also fulfilled the criteria for pathologically defined sporadic IBM (Benveniste and Hilton-Jones, 2010; Hilton-Jones et al., 2010) . Forty-five patients fulfilled the criteria for possible sporadic IBM (Griggs et al., 1995) i.e. presence of vacuoles and partial invasion of muscle fibres on muscle biopsy and characteristic clinical features, all of whom fulfilled the criteria for clinically defined sporadic IBM (Benveniste and Hilton-Jones, 2010; Hilton-Jones et al., 2010) (i.e. duration of weakness 412 months, age 435 years, weakness of finger flexion 4 shoulder abduction and of knee extension 4 hip flexion, with muscle biopsy showing endomysial inflammatory infiltrates with or without partial invasion, or increased MHC-I, but no intracellular amyloid deposits or 15-18 nm filaments). The 51 remaining patients fulfilled the criteria for clinically defined sporadic IBM (Benveniste and Hilton-Jones, 2010; Hilton-Jones et al., 2010) with, on muscle biopsy, inflammation (without invaded fibres) and/or increased MHC-I and/or vacuoles but no intracellular amyloid deposits or tubulofilaments (mostly by absence of specific assessment at the time of original diagnosis). As shown in Table 3 , no statistical differences were observed between these three groups of patients. Finally, 107 (81.1%) patients had inflammation, 85 (62.5%) partially invaded fibres and 98 (74.2%) vacuoles. As part of a separate study, we have retrospectively looked at 34 of these biopsies with inflammation and vacuoles, using TPD-43 and p62 antibodies, and all contained sarcoplasmic deposits within vacuolated and non-vacuolated fibres. It is noteworthy that 42 patients (30%) had had an initial incorrect diagnosis (mostly polymyositis; Table 2 ). The median age of first symptoms was 61 years and 67 years for sporadic IBM diagnosis (biopsy). Sixteen (11.8%) patients had their first symptoms before the age of 50 years and 44 (32.3%) between 50 and 59 years. Sixty-five per cent of males presented with their first symptoms after the age of 60 years versus 43% for females (P = 0.01). At the last visit (Table 2) , the median age of (Fig. 1) . Overall, 71 (52%) patients received at least one immunosuppressive treatment (Table 4) for a median duration of 40.8 months. As expected, patients from Paris received these treatments more frequently than those in Oxford (71% versus 27%, P 5 0.001). Prednisone (initial dose of 1 mg/kg/day) was the most frequently prescribed drug (91.5%) and was used in association with other immunosuppressants in 64.8% (Table 4) . Treated patients were younger at onset of first symptoms and had more frequently received a previous misdiagnosis of polymyositis than untreated patients (Table 5) . Age, grip test, creatine kinase level and number of deceased patients were not different between treated and untreated patients, while Walton scale, Rivermead Mobility Index and IWCI reflected more severe weakness among treated patients (Table 5) .
Statistical analysis
During their follow-up, 103 patients reported walking difficulties, of whom 51 needed to use a wheelchair. Overall 25 patients died. The first stage of disease progression towards handicap for walking was more rapid among males (hazard ratio = 2.4, P = 0.0004), patients older at first symptoms (hazard ratio = 2.0, P = 0.003) and patients receiving immunosuppressive treatments (hazard ratio = 2.0, P = 0.002) (Table 6 ). However, after a walking aid was needed, rate of progression towards the use of a wheelchair was not associated with gender, age or treatments. The median delay between the onset of the disease and the use of a wheelchair was 14 years (95% CI 13-18). The risk of death was only influenced by older age at the time of first symptoms. Based on life expectancy tables, male and female individuals aged 60 years can expect to live 21.6 and 26.5 additional years, respectively. For individuals aged 70 years, the numbers of expected additional life years are 14.2 years (males), and 17.9 years (females). Compared with the life expectancy that patients with sporadic IBM could have expected when they presented their first symptoms, survival of patients with sporadic IBM was not diminished with a median fraction of normal remaining life of 88% (95%CI 76-130). There were no differences in the fraction of normal remaining life curves for patients with sporadic IBM stratified by age at first symptoms, and the estimated probability of surviving at least half of normal remaining life was 90% whatever the age at first symptoms.
Discussion
This study, reviewing 136 patients from two European centres, is the largest on sporadic IBM to date. Our first goal was to describe the progression of sporadic IBM. This has been reported only in one prospective natural history study (Rose et al., 2001 ); during a 6-month period, observation of 11 patients showed that there was an overall decline in muscle strength of 4% from baseline. The prospective clinical trial of Campath Õ (Dalakas et al., 2009) involved 13 patients and showed during the 1 year observation period before treatment that the patients' total strength declined by a mean of 14.9%. The rarity of truly prospective natural history Beyenburg et al., 1993; Lindberg et al., 1994; Amato et al., 1996; Peng et al., 2000; North, 2001 Badrising et al., 2005) ( Table 7) . The sex distribution, the mean age at onset of symptoms and the mean age at diagnosis were comparable between these studies and the present one (Table 7) . The present study included all patients diagnosed with sporadic IBM in the two participating centres between 1990 and 2008. Much detailed information was available for all included patients; 52% of them were reviewed during a clinic giving the opportunity to undertake a more complete physical examination that allowed us to calculate a new sporadic IWCI. This index of severity of weakness was easy to perform during a clinic. Conventional assessments in neuromuscular disorders have included MRC strength measurements and sum scores. These work well for diseases with widespread/generalized weakness, but less well in conditions, such as sporadic IBM, in which there is a striking involvement of certain muscles and sparing of others. Thus, in early stages of sporadic IBM there is characteristic weakness of finger flexion and knee extension, with all other muscle groups being of normal strength. Given difficulties with the limitations of MRC to reflect change over a fairly broad area of strength measurement, we decided to use more quantifiable measures of strength/function, in the form of times (easily measured) for various functions. The proposed IWCI-evaluated muscles (force of hand flexor and quadriceps) and functions (limb girdle, axial weakness, swallowing difficulties) particularly affected by sporadic IBM. A correlation was observed between IWCI and grip strength or Rivermead Mobility Index. Overall, the IWCI decreased with disease duration since first symptoms, and onset of use of assistive devices, which is a useful and previously reported marker of disease progression (Peng et al., 2000) . We propose that this IWCI might be a valuable outcome measure for future clinical trials. Nevertheless, it still has to be validated in a prospective natural history study of sporadic IBM and compared with other outcomes, such as quantitative myometry (Rose et al., 2001) , IBM functional rating scale (Jackson et al., 2008) , handgrip, 6 min walk test and manual muscle testing.
Even with the wealth of information available, the limitations of this study must also be considered. Our cohort is representative of general clinical management for this disease with some patients under regular review in specialist reference centres, while others had only infrequent or 'once only' specialist referral visits. Information about presenting features was recorded retrospectively, based on patient interview and/or medical records.
This study emphasizes the failings, or at least limitations, of established diagnostic criteria. Currently, the diagnosis of 'definite sporadic IBM' is based entirely on pathological criteria (Griggs et al., 1995; Dalakas, 2006; Needham and Mastaglia, 2007) . These were fulfilled by one-third of our patients, even though the search for phosphorylated-tau and amyloid protein deposits was not performed routinely at the time of diagnosis. For the remaining patients, where the canonical pathological criteria are lacking, specific clinical features become more important in establishing the diagnosis. Such features, although included in some diagnostic categories, were arguably given less precedence than pathological features in the design of currently accepted consensus diagnostic criteria (Griggs et al., 1995; Dalakas, 2006; Needham and Mastaglia, 2007) , mainly because of differing views on the specificity of these features. It has long been recognized that it is the absence of the canonical pathological features that leads to the common clinical difficulty of distinguishing between polymyositis and sporadic IBM. Thus, one-third of our patients had an initial incorrect diagnosis (most frequently of polymyositis). It was then the resistance to immunosuppressive drugs and/or the change in clinical phenotype, with the development of asymmetric distal involvement (e.g. of flexors in the forearms), that led us to perform a second (or third) biopsy and finally make the diagnosis of sporadic IBM. This situation has been described as forming the group of unresponsive polymyositis (Amato et al., 1996) or patients with polymyositis/IBM (Chahin and Engel, 2008) where clinical features, resistance to immunosuppressors and progression are not different from sporadic IBM, but the canonical pathological findings of sporadic IBM were absent. On the basis of the literature and extensive personal experience, the consensus of participants of two recent sporadic IBM workshops (Benveniste and Hilton-Jones, 2010; Hilton-Jones et al., 2010) was that both patients with 'clinically defined sporadic IBM' and patients with 'pathologically clinically defined sporadic IBM' should be eligible for future clinical trials with separate analysis of response to treatment. Finally, our study has shown that no statistical differences can be evidenced between these groups of patients (Table 3) , reinforcing the view that all of these patients indeed had sporadic IBM. Because of the number of enrolled patients, we were able to establish that sporadic IBM is a disabling disease leading to wheelchair use after a median of 14 years. This rate of progression was not calculated in previous studies (Ringel et al., 1987; Lotz et al., 1989; Sayers et al., 1992; Beyenburg et al., 1993; Lindberg et al., 1994; Amato et al., 1996; Peng et al., 2000; Felice and North, 2001; Badrising et al., 2005) . Disease progression towards handicap with respect to walking was more rapid among patients who were older at first symptoms. This was also observed by Peng et al. (2000) , who showed that patients progress faster to disability when symptoms begin after the age of 60. There are several possible explanations for this observation. Younger patients may have more reserves in the form of muscle mass, which physiologically reduces with age. Older patients may also have co-morbidities that affect their mobility such as degenerative joint disease, stroke, etc. We also observed that first symptoms occurred more frequently after the age of 60 years in males than in females. Badrising et al. (2005) also noticed that females had a longer duration of symptoms; we noted more rapid progression among males. This different rate of progression between males and females could be explained in part by the fact that males have greater muscle bulk than females. The pathological onset of the disease may be at the same age for the two sexes, but males have more muscle in reserve, which delays the onset of symptomatic weakness. But once the weakness becomes apparent, the faster rate of disease progression in males may simply reflect their greater age.
This study is also the first to demonstrate clearly that life expectancy is generally not affected by sporadic IBM, despite the disability due to the disease, as shown by comparison of the survival curves of our patients to those of the general population. Expectation of life at selected ages for the English general population are similar to the French statistics for males, but females have a slightly shorter life expectancy in England than in France (http://www.statistics.gov.uk/STATBASE/ssdataset.asp?vlnk = 9551). Application of the French life expectancy tables to patients from both centres could have therefore underestimated the fraction of normal remaining life span for patients with sporadic IBM, limiting bias for survival estimates. This does not detract from our conclusion that sporadic IBM does not in itself significantly limit life expectancy. However, it must also be recognized that undoubtedly some deaths relate indirectly to the disease, most obviously from pneumonia, which may be contributed to by aspiration from the associated dysphagia and by general immobility (Peng et al., 2000) .
A further goal of the study was to look for any evidence from the available data that immunosuppressant therapy altered the natural history of the condition. With respect to mortality, the numbers were not different between the treated and untreated groups. Considering morbidity, the Walton and Rivermead Mobility Index scales and IWCI indicated more severe weakness at last examination among the treated patients, who were also more likely to present with handicap for walking. It also appeared that the rapidity of progression towards the use of a walking aid was greater in treated patients. This apparent deleterious effect of the immunosuppressants could reflect that more severely affected patients have been treated in preference to those less severely affected, as reported in randomized short-term studies (Leff et al., 1993; Dalakas et al., 1997 Dalakas et al., , 2001 Walter et al., 2000; Muscle Study Group, 2001 , 2004 Badrising et al., 2002; Rutkove et al., 2002) . As this study was not a prospective trial, we cannot compare the strength of the patients at the time of treatment initiation, and thus cannot exclude this possibility. However, against it, we saw that younger patients were more frequently treated than older, and overall these were the patients who were the less severely affected. A second possibility is that these treatments are actually deleterious to muscle strength. Corticosteroids are indeed known to induce myopathy (Askari et al., 1976; Batchelor et al., 1997) , especially in elderly people, and that might have aggravated the weakness due to sporadic IBM. While accepting all of the limitations that have been discussed, the data from our study rather strongly suggest that immunomodulatory therapy does not have a major beneficial effect in patients with sporadic IBM. Future prospective double-blind studies are required to confirm or refute our findings, and they must also look closely at side-effects of treatment to establish the risk : benefit ratio.
In conclusion, this study showed that in our population, sporadic IBM started on average in the sixth decade of life and then slowly progressed. It took a median of 14 years to get from first symptoms to the need to use a wheelchair. The disease is not usually the cause of death. Immunosuppressant drug therapies were not only shown to be of no benefit but, by several measures, appear to have modestly exacerbated progression of disability. We accept that the inherent limitations of our study do not allow absolute confirmation of this observation, which requires further assessment. On current evidence, therapeutic trials of immunosuppression using conventional agents do not appear to be justified in cases of definite sporadic IBM. We have proposed a simple clinical assessment tool, the IWCI, which may prove valuable in future natural history and therapeutic studies, but which requires further evaluation and validation.
